This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection (NCT02716779), a randomized phase 2 study. The primary outcome is Log Likelihood Median Values of Hepatitis C-Virus (HCV) Kinetic Models for Quantitative HCV Ribonucleic Acid (RNA) Measurement With Various Assumptions of Ribavirin Mechanism of Action.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT02716779 |
| Phase | Phase 2 |
| Condition | Hepatitis C, Chronic |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Double |
| Enrollment | 68 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Hoffmann-La Roche |
| Results posted | Yes |
2. Clinical Question
Population
Treatment-naïve participants with chronic hepatitis C virus genotype 1 infection. The primary endpoint specifies a Per Protocol population: participants who completed 6 weeks of monotherapy and at least 4 weeks of combination therapy, had quantitative HCV-RNA measurements at baseline, period 1 and period 2, and had no major protocol violations or treatment interruption. The population description also includes a dose-reduction criterion, but its text is cut off in the registry record.
Intervention
Ribavirin monotherapy for 6 weeks, followed by PEG-IFN alfa-2a plus ribavirin for 12 weeks. The initial ribavirin dose was 1000 milligrams to 1200 mg orally daily depending on body weight.
Comparator
Ribavirin-matching placebo for 6 weeks, or PEG-IFN alfa-2a monotherapy for 6 weeks. Both groups then received PEG-IFN alfa-2a plus ribavirin for 12 weeks. PEG-IFN alfa-2a was given at 180 micrograms subcutaneously weekly.
Primary question
How do virus-kinetic models that assign ribavirin’s effect to infectiousness, virus production or the degradation rate of infected cells fit quantitative HCV-RNA data? Model fit is assessed using log likelihood function values, with a lower value indicating a lesser fit.
The central comparison is about the initial treatment period, when the groups received different monotherapies or placebo, before all participants moved to combination therapy. This structure is intended to examine how the initial ribavirin exposure relates to early viral kinetics. It is not a comparison of three distinct long-term regimens: the treatment paths converged after the initial 6 weeks.
The registry describes three randomized groups and identifies the study as a Phase II, parallel-group, partially double-blinded, placebo-controlled trial. It records 68 participants enrolled. If an initial virological response was present after 12 weeks of combination therapy, treatment could continue for a further 36 weeks outside the study. The primary endpoint timeframe is stated as up to Day 126.
The primary question is mechanistic and model-based rather than a direct question about a single clinical response rate. It asks which assumed mechanism yields a better fit to the observed viral-kinetic data. The registry record does not report the numerical model-fit results, so it does not establish which mechanism fit best or how uncertain any difference in fit may be.
3. Trial Design
This was a randomized, multicentric, parallel-group Phase II study with placebo control and partial double blinding. Participants were treatment-naïve and had chronic hepatitis C virus genotype 1 infection. The registry records 68 participants enrolled and identifies Hoffmann-La Roche as the sponsor. The study status is completed.
Participants were assigned to one of three initial six-week treatment conditions. One group received ribavirin monotherapy, one received a matching placebo, and one received PEG-IFN alfa-2a monotherapy. The ribavirin dose was 1000 milligrams to 1200 mg orally daily depending on body weight; PEG-IFN alfa-2a was 180 micrograms subcutaneously weekly. The record does not give the randomization ratio, the allocation sequence method, or details of any stratification.
After the initial monotherapy or placebo period, participants in all groups received PEG-IFN alfa-2a plus ribavirin for 12 weeks. Participants with an initial virological response after that combination-treatment period could continue treatment for a further 36 weeks outside the study. Thus, the randomized contrast centers on the first treatment period; subsequent treatment was common across groups within the study.
The primary endpoint was based on quantitative HCV-RNA measurements and the fit of virus-kinetic models through up to Day 126. The primary analysis population is described as Per Protocol. It required 6 weeks of monotherapy, at least 4 weeks of combination therapy, measurements at baseline, period 1 and period 2, no major protocol violations, and no treatment interruption. The dose-reduction condition is truncated in the registry record, so its full wording is not reported there.
Although the registry includes intervention descriptions and selected safety counts, it does not report arm-level primary endpoint estimates, a full statistical analysis plan, or the randomization details. It also does not report how participants were distributed across the randomized groups in the enrollment description. The safety risk sets are not a substitute for randomized group sizes because they are presented for specific treatment periods and safety outcomes.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: Enrollment was 68: 1 participant withdrew during the screening phase and 67 participants were randomized.
Monotherapy
| Stage | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| STARTED | 14 | 26 | 27 |
| COMPLETED | 14 | 25 | 26 |
| NOT COMPLETED | 0 | 1 | 1 |
Reasons for not completing this period:
| Reason | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Adverse Event | 0 | 1 | 1 |
Combination Therapy
| Stage | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| STARTED | 14 | 25 | 26 |
| COMPLETED | 14 | 23 | 25 |
| NOT COMPLETED | 0 | 2 | 1 |
Reasons for not completing this period:
| Reason | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin |
|---|---|---|---|
| Adverse Event | 0 | 2 | 1 |
Analysis population for the primary outcome, as defined in the registry: Per Protocol (PP) population: participants with 6 weeks of monotherapy and at least 4 weeks combination therapy as well as three quantitative HCV-RNA measurements (baseline, period 1, period 2), no major protocol violations, no treatment interruption and no dose reduction below 80% of the planned medication within the first 10 therapy weeks.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Pegylated Interferon (PEG-IFN) Alfa-2a | Placebo | Ribavirin | Total |
|---|---|---|---|---|---|
| Participants analysed | 14 | 26 | 27 | 67 | |
| Age, Continuous | years | 45.8 (SD 14.4) | 48.2 (SD 15.4) | 50.2 (SD 12.9) | 48.5 (SD 14.1) |
| Sex: Female, Male: Female | Participants | 7 | 18 | 17 | 42 |
| Sex: Female, Male: Male | Participants | 7 | 8 | 10 | 25 |
6. Primary Endpoint
The registry lists the primary outcome as Log Likelihood Median Values of Hepatitis C-Virus (HCV) Kinetic Models for Quantitative HCV Ribonucleic Acid (RNA) Measurement With Various Assumptions of Ribavirin Mechanism of Action, measured over Up to Day 126.
| Element | Registry entry |
|---|---|
| Result type | Median |
| Measure of spread | 95% Confidence Interval |
| Unit | log likelihood function value |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint is the median log likelihood function value from virus-kinetic models fitted to quantitative HCV-RNA measurements, with a 95% confidence interval and a timeframe up to Day 126. The registry describes three model assumptions: ribavirin has an individual effect on infectiousness, on virus production, or on the degradation rate of infected cells. Each model also fitted the initial viral load, the loss rate of infected cells (delta), and interferon effectiveness in a pharmacokinetic-pharmacodynamic model.
Likelihood values describe how well a specified statistical model fits the observed data under its assumptions. The registry states that a lower log likelihood function value indicates a lesser fit for the model. This direction matters when interpreting the endpoint: a lower value should not be read as better fit based on the registry’s own definition. The endpoint is designed to compare model fit under alternative mechanistic assumptions, not to measure a patient’s quality of life or to report a single treatment-response percentage.
The median describes the central value of the reported distribution, while a confidence interval communicates uncertainty around an estimate. In general, a wider interval indicates less precision than a narrower interval, though interpretation also depends on what quantity the interval covers and how it was constructed. The registry does not report the actual medians or confidence interval limits for the primary endpoint, nor does it state a formal statistical test comparing the models. Consequently, the endpoint definition is available, but its numerical findings are not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record sets out a model-fitting endpoint but does not report numerical primary endpoint results. It therefore does not show the median log likelihood values or their 95% confidence intervals for the models that assume effects on infectiousness, virus production, or infected-cell degradation. The record’s direction for interpreting fit is explicit: a lower log likelihood function value indicates a lesser fit. Without the model-specific values, it is not possible to identify which assumption fit the viral-kinetic data best from the registry record.
This endpoint should be distinguished from a direct measure of virological response. The study description discusses initial virological response and includes treatment response among secondary outcomes, but the primary endpoint is the fit of models to quantitative HCV-RNA measurements. A model’s fit addresses how well its assumptions describe the observed data; it does not by itself establish a clinical benefit or determine whether a treatment should be used.
Precision cannot be assessed from the posted primary outcome information because the interval limits are not reported. The record specifies a 95% confidence interval as the dispersion measure, but does not provide its values. A confidence interval ordinarily conveys the uncertainty associated with an estimate under the analysis method. Without its limits, readers cannot assess how concentrated or uncertain the model-fit estimates were, nor whether the models’ estimates were distinguishable in practical or statistical terms.
The registry describes three initial treatment groups, followed by common combination therapy. This design makes the initial six-week period especially important for interpreting the randomized contrasts. Once participants entered combination therapy, the treatment paths converged. The primary timeframe extends up to Day 126, and the analysis population required a minimum period of combination treatment and measurements at specified stages. These conditions mean the primary endpoint applies to the stated Per Protocol population rather than necessarily to every randomized participant.
Results for participant response, quality of life, and pharmacokinetic outcomes are listed among the secondary outcomes, but numerical results for those outcomes are not reported in the registry record. The safety record does include counts of serious and other events by treatment period, but those counts do not resolve the primary mechanistic question. Neither a lack of numerical primary results nor the absence of a posted comparison should be interpreted as evidence for or against any treatment effect.
Planning illustrations based on an observed effect are not observed power and do not supply the missing endpoint estimates. The stated planning approach assumes a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; it considers effects defined as a fraction of the observed effect. Those assumptions describe a planning calculation, not the trial’s original sample-size justification, which is not reported in the registry record. The illustrations cannot establish what the trial was designed to detect or how likely it was to identify an effect.
9. Statistical Methods Explained
The primary endpoint uses likelihood-based model fitting. In general, a likelihood summarizes how compatible observed data are with a model’s assumptions and parameter values. Here, the models were fitted to virus-kinetic data from quantitative HCV-RNA measurements. The registry describes three alternative assumptions about ribavirin’s action: an effect on infectiousness, an effect on virus production, or an effect on the degradation rate of infected cells. The models also included initial viral load, the loss rate of infected cells (delta), and interferon effectiveness in a pharmacokinetic-pharmacodynamic model.
What does a model-fit value tell the reader?
A model-fit statistic is not automatically a measure of treatment benefit. It addresses how the model represents the observed data. The registry states that a lower log likelihood function value indicates a lesser fit, so the direction of interpretation must follow that definition. The listed endpoint is the median of these values, with a 95% confidence interval. Without the model-specific medians and interval limits, readers cannot rank the three assumptions by fit or assess the precision of the estimates.
The word “median” indicates that the endpoint summarizes a distribution using its central value rather than its arithmetic mean. The registry does not describe the distribution of individual model-fit values or explain the procedure used to construct the confidence interval. Those details, along with any formal comparison procedure among models, are not reported in the registry record. No result can be inferred merely from the fact that the models were fitted.
Why do model assumptions matter?
Each model gives a different account of how ribavirin might affect virus kinetics. If a model assumes an effect on infectiousness, it represents that mechanism differently from a model assuming altered virus production or a changed rate of infected-cell degradation. Comparing fit can help assess whether the observed data are more compatible with one specified representation than another. This is a statistical comparison of descriptions of the data; it is not a direct demonstration that the assumed biological mechanism is uniquely correct.
More than one model can describe data plausibly, and model fit depends on the chosen structure and fitted parameters. A fit comparison is most informative when its methods and results are fully reported, including any criteria for comparing models and the uncertainty in those comparisons. The registry record identifies the model assumptions and the measured endpoint, but the numerical estimates and additional comparison methods are not reported there.
What does the confidence interval add?
In general, a confidence interval gives a range of values compatible with an estimate under the assumptions of the statistical procedure. Its width provides information about precision, but it does not remove uncertainty or guarantee that the model is correctly specified. The endpoint lists a 95% confidence interval as its dispersion measure. Since the interval bounds are absent, the precision of each median cannot be evaluated from the registry record. There is also no basis in the posted information for determining whether intervals overlap or for using overlap as a substitute for a formal comparison.
The trial’s endpoint timeframe is up to Day 126. The primary population is described as Per Protocol and requires sufficient treatment exposure, specified HCV-RNA measurements, and the absence of major protocol violations and treatment interruption. Such criteria define which participants contribute to the stated primary analysis. In general, a Per Protocol analysis can differ from an analysis that retains all randomized participants, because eligibility for analysis depends on post-randomization adherence and data availability. The registry does not report a corresponding intention-to-treat result or explain how missing measurements were handled.
How should the planning illustrations be read?
Sample-size calculations based on an observed effect are planning illustrations. They estimate the number of participants that would be needed under specified assumptions to detect a chosen effect, rather than reporting the trial’s observed ability to detect an effect. The registry describes an illustration using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It considers a target effect defined as a stated fraction of the observed effect. The illustration does not represent the trial’s own design justification, and its assumed two-arm comparison should not be mistaken for a complete analysis of the study’s three initial groups or its multiple model assumptions.
Such calculations depend on the effect size selected and on the assumptions used in the calculation. If the effect estimate used for planning is uncertain, the resulting sample-size illustration is uncertain as well. The registry does not report the original sample-size justification or its assumptions. Any planning numbers associated with the illustration should therefore be read as hypothetical requirements under those assumptions, not as observed power and not as evidence that the study was adequately or inadequately powered.
Why can over-dispersion matter?
In general, over-dispersion means that observed variability is greater than a model’s assumed variability. If a model does not account for that extra variation, its uncertainty estimates can be too optimistic and its inferential conclusions may be unreliable. This is a general statistical consideration, not a feature reported for this trial. The registry does not report whether over-dispersion was assessed or how it was handled.
Other methodological details, including the complete analysis plan, model diagnostics, parameter-estimation method, missing-data procedures, and any adjustment for multiple comparisons, are not reported in the registry record. Those omissions limit independent assessment of how robust the model-based conclusions would be, even if numerical results were available.
10. Multiplicity, Missing Data and Analysis Populations
The study has several outcomes and several plausible comparisons. The primary endpoint itself involves three virus-kinetic models with different assumptions about ribavirin’s mechanism. The registry also lists secondary outcomes covering quality of life, treatment response, and pharmacokinetic measures for ribavirin and PEG-IFN. Considering multiple outcomes or model comparisons raises the general issue of multiplicity: when many statistical questions are examined, the chance of at least one apparently notable result can increase unless the analysis plan addresses that issue.
The registry record does not report whether multiplicity was controlled, whether one model comparison was designated as the main contrast, or how any secondary analyses were to be interpreted. It does not provide a full statistical analysis plan or numerical primary and secondary outcome results. It is therefore not possible to determine how the investigators handled the multiple outcomes and model assumptions, or whether reported inference—if available elsewhere—would be adjusted for multiple testing.
Missing-data methods are also not reported in the registry record. The primary population requires quantitative HCV-RNA measurements at baseline, period 1 and period 2, as well as specified treatment exposure and protocol adherence. These criteria make measurement availability and post-randomization eligibility relevant to interpretation. The registry does not state how participants lacking measurements were handled, whether any imputation was used, or how missingness was assessed.
The stated primary population is Per Protocol, not an all-randomized analysis. Its criteria include 6 weeks of monotherapy, at least 4 weeks of combination therapy, no major protocol violations, and no treatment interruption. The dose-reduction wording is truncated after “below 80% of the planned me” in the registry record, so the full criterion is not available. The record does not report an intention-to-treat analysis or a sensitivity analysis addressing departures from the Per Protocol population. As a result, the extent to which the primary findings would generalize to all randomized participants cannot be evaluated from the registry record.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| PEG-IFN Alfa-2a, Period 1 Monotherapy | 0 | 14 | 0.0% |
| Placebo, Period 1 Monotherapy | 1 | 26 | 3.8% |
| Ribavirin, Period 1 Monotherapy | 0 | 27 | 0.0% |
| PEG-IFN Alfa-2a, Period 2 Combination Therapy | 0 | 14 | 0.0% |
| Placebo, Period 2 Combination Therapy | 2 | 25 | 8.0% |
| Ribavirin, Period 2 Combination Therapy | 2 | 26 | 7.7% |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| PEG-IFN Alfa-2a, Period 1 Monotherapy | 9 of 14 |
| Placebo, Period 1 Monotherapy | 9 of 26 |
| Ribavirin, Period 1 Monotherapy | 12 of 27 |
| PEG-IFN Alfa-2a, Period 2 Combination Therapy | 12 of 14 |
| Placebo, Period 2 Combination Therapy | 23 of 25 |
| Ribavirin, Period 2 Combination Therapy | 24 of 26 |
Most frequent serious adverse event terms
| Event term | Organ system | PEG-IFN Alfa-2a, Period 1 Monotherapy | Placebo, Period 1 Monotherapy | Ribavirin, Period 1 Monotherapy | PEG-IFN Alfa-2a, Period 2 Combination Therapy | Placebo, Period 2 Combination Therapy | Ribavirin, Period 2 Combination Therapy |
|---|---|---|---|---|---|---|---|
| Depression | Psychiatric disorders | 0 of 14 | 1 of 26 | 0 of 27 | 0 of 14 | 1 of 25 | 0 of 26 |
| Retinal haemorrhage | Eye disorders | 0 of 14 | 0 of 26 | 0 of 27 | 0 of 14 | 1 of 25 | 0 of 26 |
| Otitis media | Infections and infestations | 0 of 14 | 0 of 26 | 0 of 27 | 0 of 14 | 0 of 25 | 1 of 26 |
| Urinary tract infection | Infections and infestations | 0 of 14 | 0 of 26 | 0 of 27 | 0 of 14 | 0 of 25 | 1 of 26 |
| Psychotherapy | Surgical and medical procedures | 0 of 14 | 0 of 26 | 0 of 27 | 0 of 14 | 0 of 25 | 1 of 26 |
Most frequent non-serious adverse event terms
| Event term | Organ system | PEG-IFN Alfa-2a, Period 1 Monotherapy | Placebo, Period 1 Monotherapy | Ribavirin, Period 1 Monotherapy | PEG-IFN Alfa-2a, Period 2 Combination Therapy | Placebo, Period 2 Combination Therapy | Ribavirin, Period 2 Combination Therapy |
|---|---|---|---|---|---|---|---|
| Headache | Nervous system disorders | 2 of 14 | 4 of 26 | 4 of 27 | 2 of 14 | 10 of 25 | 5 of 26 |
| Fatigue | General disorders | 3 of 14 | 1 of 26 | 4 of 27 | 0 of 14 | 9 of 25 | 6 of 26 |
| Nausea | Gastrointestinal disorders | 2 of 14 | 2 of 26 | 1 of 27 | 4 of 14 | 8 of 25 | 5 of 26 |
| Influenza like illness | General disorders | 3 of 14 | 0 of 26 | 0 of 27 | 1 of 14 | 5 of 25 | 9 of 26 |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 2 of 14 | 0 of 26 | 1 of 27 | 2 of 14 | 2 of 25 | 4 of 26 |
| Pruritus | Skin and subcutaneous tissue disorders | 0 of 14 | 0 of 26 | 0 of 27 | 1 of 14 | 5 of 25 | 4 of 26 |
| Decreased appetite | Metabolism and nutrition disorders | 1 of 14 | 0 of 26 | 1 of 27 | 0 of 14 | 4 of 25 | 3 of 26 |
| Sleep disorder | Psychiatric disorders | 0 of 14 | 1 of 26 | 2 of 27 | 0 of 14 | 4 of 25 | 2 of 26 |
| Diarrhoea | Gastrointestinal disorders | 1 of 14 | 0 of 26 | 1 of 27 | 0 of 14 | 5 of 25 | 1 of 26 |
| Pyrexia | General disorders | 1 of 14 | 0 of 26 | 0 of 27 | 1 of 14 | 3 of 25 | 3 of 26 |
Serious events with the highest arm-level rate: depression (4.0%), retinal haemorrhage (4.0%), otitis media (3.8%), urinary tract infection (3.8%), psychotherapy (3.8%).
The registry reports serious-event and other-event counts separately for the monotherapy and combination-treatment periods. During monotherapy, the PEG-IFN alfa-2a group had 0 serious events among 14 at risk and 9 other events among 14 at risk; the placebo group had 1 serious event among 26 at risk and 9 other events among 26 at risk; and the ribavirin group had 0 serious events among 27 at risk and 12 other events among 27 at risk.
During combination therapy, the PEG-IFN alfa-2a group had 0 serious events among 14 at risk and 12 other events among 14 at risk; the placebo group had 2 serious events among 25 at risk and 23 other events among 25 at risk; and the ribavirin group had 2 serious events among 26 at risk and 24 other events among 26 at risk. These are counts within the registry’s treatment-period categories. They should not be read as adjusted comparisons or as evidence that one treatment caused an event.
The record lists depression and retinal haemorrhage at 4.0%, and otitis media, urinary tract infection, and psychotherapy at 3.8%, among the top serious terms. The registry does not clarify in this listing the denominator or analysis basis for these percentages. Death counts are not reported in the registry record. The safety information is descriptive and does not include enough detail to establish comparative risks or explain differences between treatment periods.
12. What the Result Does, and Does Not, Mean
The record describes a trial designed to examine whether early exposure to ribavirin influences viral kinetics in treatment-naïve participants with chronic hepatitis C genotype 1. Participants were randomized among ribavirin monotherapy, matching placebo, or PEG-IFN alfa-2a monotherapy for 6 weeks, followed by combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks. The primary endpoint was model fit for alternative assumptions about ribavirin’s mechanism.
That design can frame a statistical question about how different virus-kinetic models represent observed HCV-RNA data. It does not, by itself, establish that one assumed mechanism is true, or that a model’s fit translates into a clinical outcome. The registry’s own endpoint description says that lower log likelihood function values indicate a lesser fit. Numerical values and confidence intervals for the models are not reported in the registry record, so the posted information does not identify a best-fitting model or show the precision of the estimates.
The record also does not provide numerical results for the listed secondary outcomes, including quality of life, treatment response, and pharmacokinetic measures. The presence of these outcomes in the registry is not evidence of a particular result. Similarly, the safety counts describe events in specified periods but do not establish causal relationships or comparative risk. They should be interpreted as reported counts, with the limitations of the record’s detail.
The primary analysis population is Per Protocol and depends on treatment exposure, protocol adherence, and availability of measurements at specified periods. It is therefore important not to assume that the stated endpoint represents every randomized participant. Missing-data methods and an intention-to-treat analysis are not reported in the registry record.
In general, a registry entry can describe the planned question and selected outcome definitions without providing the numerical results needed to evaluate the evidence. For this study, the key distinction is between a detailed endpoint description and an absent numerical result. The record supports describing what was intended to be measured and how the treatment periods were arranged; it does not support a conclusion about the direction, magnitude, statistical significance, or clinical importance of the primary endpoint.
13. Why This Trial Matters Statistically
This trial is statistically notable because its primary question is mechanistic and depends on comparing alternative virus-kinetic model assumptions. The endpoint is not a simple difference in a single clinical measurement. Instead, it uses median log likelihood values to describe how models fit quantitative HCV-RNA data when ribavirin’s effect is represented through infectiousness, virus production, or infected-cell degradation.
That structure illustrates why model definition matters. A statistical model organizes the data according to assumptions about the process being studied. Different assumptions can lead to different representations of the same viral-kinetic measurements. Fit statistics can help assess those representations, but model fit alone does not confirm a biological mechanism. The registry’s direction for interpreting the log likelihood values is particularly important: it states that a lower value indicates a lesser fit.
The randomized design also separates an initial six-week period, when participants received different monotherapies or placebo, from the later period, when all groups received combination therapy. That treatment sequence focuses the randomized contrast on early exposure while making the endpoint’s timing and analysis population important to interpret. The primary analysis is Per Protocol and includes eligibility requirements based on treatment and measurements.
The registry record also illustrates the limits of statistical interpretation when outcome definitions are available without numerical results. It names the endpoint, model assumptions, timeframe, and confidence-interval measure, yet does not report the medians, interval bounds, or model comparisons. Those missing results prevent assessment of fit, precision, or the relative support for the competing assumptions. The study is therefore useful as an example of the distinction between a well-specified statistical question and the evidence needed to answer it.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The main limitation for interpreting the trial’s statistical findings is that numerical primary endpoint results are not reported in the registry record. The record gives the endpoint definition, model assumptions, timeframe, and confidence-interval measure, but not the model-specific medians or confidence interval limits. Without those results, the direction and precision of model-fit estimates cannot be assessed, and no comparison among the assumptions can be drawn from the registry entry.
The registry also does not report a formal test or decision rule for comparing the models. Details of model diagnostics, parameter estimation, and assessment of model assumptions are not reported. Because the endpoint is model-based, these details would help readers evaluate whether the fitted models adequately represent the viral-kinetic data and how sensitive conclusions might be to modeling choices.
The listed primary population is Per Protocol. Eligibility depends on treatment exposure, measurements at specified time points, and protocol adherence. The record does not give an intention-to-treat analysis, missing-data handling, or sensitivity analyses to evaluate the implications of excluding participants from the primary population. The Per Protocol description is also truncated in its dose-reduction criterion after “below 80% of the planned me,” leaving the full wording unavailable.
The registry does not report the multiplicity strategy, the full statistical analysis plan, or the original sample-size justification. Planning illustrations based on the observed effect are not a substitute for the original design rationale and are not observed power. Safety information is reported as counts for treatment periods, without enough detail to infer adjusted comparisons or causation. Death counts are not reported in the registry record.
Finally, treatment paths converge after the initial 6 weeks because all groups receive PEG-IFN alfa-2a plus ribavirin for 12 weeks. This design is suited to a question focused on the initial period, but the primary endpoint should not be interpreted as a direct randomized comparison of distinct long-term regimens. Continuation for a further 36 weeks occurred outside the study for participants with an initial virological response after 12 weeks of combination therapy.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection — NCT02716779.
- Registry record last updated 2016-08-22; status last verified 2016-03.
- Results first posted 2016-07-14.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry describes a completed, randomized, parallel-group, partially double-blinded, placebo-controlled Phase II study sponsored by Hoffmann-La Roche. It enrolled 68 treatment-naïve participants with chronic hepatitis C genotype 1 infection. Initial treatment for 6 weeks was ribavirin, matching placebo, or PEG-IFN alfa-2a monotherapy; all participants then received PEG-IFN alfa-2a plus ribavirin for 12 weeks.
The primary endpoint was the median log likelihood value for virus-kinetic models fitted to quantitative HCV-RNA data, with a 95% confidence interval and a timeframe up to Day 126. The models represented effects on infectiousness, virus production, or infected-cell degradation. The registry states that lower log likelihood values indicate a lesser fit. Numerical primary results, confidence interval limits, and formal model comparisons are not reported in the registry record.
The primary population was Per Protocol, with treatment-exposure, measurement, and protocol-adherence criteria. Selected adverse-event counts are reported by treatment period, while death counts are not reported in the registry record. Full details of multiplicity control, missing-data methods, the analysis plan, and the original sample-size justification are also not reported.